With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field

 
• By Joseph Haas

J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.

More from Strategy

More from Business